The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma

Clinical Cancer Research

Volumn 19, Issue 18, 2013, Pages 5218-5226

  Choueiri, Toni K ^a,b,c   Fay, André P ^a   Gagnon, Robert ^d   Lin, Ying ^d   Bahamon, Brittany ^b   Brown, Victoria ^b   Rosenberg, Jonathan E ^e   Hutson, Thomas E ^f   Baker Neblett, Katherine L ^d   Carpenter, Christopher ^d   Liu, Yuan ^d   Pandite, Lini ^d   Signoretti, Sabina ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d GLAXOSMITHKLINE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PAZOPANIB; PLACEBO; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VON HIPPEL LINDAU GENE;

ANGIOGENESIS INHIBITORS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; DNA, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PYRIMIDINES; SIGNAL TRANSDUCTION; SULFONAMIDES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84884583240     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0491     Document Type: Article

References (34)

1. National Cancer Institute. Surveillance epidemiology and end results (SEER). [cited 2012 Nov. 6.] Available from: http://seer.cancer.gov/statfacts/ html/kidrp.html.
2. Choueiri TK. Renal cell carcinoma. Hematol Oncol Clin North Am 2011;25: xiii-xiv.
3. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein: an update. Methods Enzymol 2007;435:371-83.
4. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
5. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, et al. Patterns of gene expression and copy-number alterations in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009;69:4674-81.
6. Farber LJ, Furge K, Teh BT. Renal cell carcinoma deep sequencing: recent developments. Curr Oncol Rep 2012;14:240-8.
7. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, et al. HIF-a effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-46.
8. Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1a and 2a on mTORC1 and mTORC2. J Biol Chem 2008;283:34495-9.
9. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28:475-80.
10. Courtney KD, Choueiri TK. Updates on novel therapies for metastatic renal cell carcinoma. Ther Adv Med Oncol 2010;2:209-19.
11. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, et al. NCCN clinical practice guidelines in oncology kidney cancer. NCCN guidelines; 2012 [cited 2012 Nov. 28]. Available from: http://www.nccn.org/ professionals/physician-gls/pdf/kidney.pdf.
12. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008;180:860-5; discussion 5-6.
13. Kaelin W G Jr. Kidney cancer: now available in a new flavor. Cancer Cell 2008;14:423-4.
14. Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, Signoretti S, et al. Genetic and functional studies implicate HIF-1a as a 14q kidney cancer suppressor gene. Cancer Discov 2011;1:222-35.
15. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
17. Guo G, Gui Y, Gao S, Tang A, Hu X, Huang Y, et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2011;44:17-9.
18. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008;14:4726-34.
19. Dondeti VR, Wubbenhorst B, Lal P, Gordan JD, D'Andrea K, Attiyeh EF, et al. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res 2012;72:112-21.
20. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393-402.
21. Li L, Kaelin WG. New insights into the biology of renal cell carcinoma. Renal cell cancer. Vol. 25. Number 4. Philadelphia, PA: Hematology/Oncology Clinics of North America; 2011. p. 667-86.
22. Biswas S, Troy H, Leek R, Chung YL, Li JL, Raval RR, et al. Effects of HIF-1a and HIF-2a on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts. J Oncol 2010;2010:757908.
23. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005;25:5675-86.
24. Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1a expression in invasive breast cancer. J Clin Pathol 2005;58:172-7.
25. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1a is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-6.
26. Patel PH, Chadalavada RS, Ishill NM, Patil S, Reuter VE, Motzer RJ, et al. Hypoxia-inducible factor (HIF) 1a and 2a levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) [presented at 2008 ASCO Annual Meeting]. J Clin Oncol 26, 2008(suppl; abstr 5008):252s.
27. Hudes GR, Pei J, Liu Y, Gagnon RC, Carpenter C, Pandite L, et al. Correlation of chromosome (Chr) 14 loss and 5q gain with outcomes of pazopanib treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC). J Clin Oncol 30, 2012(suppl; abstr 4605:303s).
28. Saez MI, Perez J M T, Perez-Rivas LG, Perez-Villa L, Villatoro R, Montesa A, et al. Hypoxia-inducible factor (HIF) 1a and 2a as predictive markers of outcome to VEGFR tyrosine kinase inhibitors (TKI) in renal cell carcinoma (RCC). J Clin Oncol 30, 2012(suppl; abstr 4630). 309s.
29. Choueiri TK, Pomerantz MM, Signoretti S. Renal-cell carcinoma: a step closer to a new classification. Lancet Oncol 2013;14:105-7.
30. Kapur P, Pena-Llopis S, Christie A, Zhrebker L, Pavia-Jimenez A, Rathmell WK, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013;14:159-67.
31. Engel KB, Moore HM. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 2011;135:537-43.
32. Di Napoli A, Signoretti S. Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer 2009;115:2290-7.
33. Signoretti S, Bratslavsky G, Waldman FM, Reuter VE, Haaga J, Merino M, et al. Tissue-based research in kidney cancer: current challenges and future directions. Clin Cancer Res 2008;14:3699-705.
34. Bahamon B, Signoretti S. Tissue biomarkers in renal cell carcinoma: intermediate endpoints in the selection of targeted agents for RCC. In: Figlin RA, Rathmell WK, Rini BI, eds. Renal cell carcinoma. Springer; New York, NY 2012. p. 69-89.